a novel G-Protein-Coupled Receptor 119 (GPR119) agonist for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). "Completion of patient dosing in the Phase 2a clinical trial ...
A seaside cape, once called home by the author of the hit novel that inspired the television series "M*A*S*H," is on the ...
Altimmune ALT is developing its lead candidate, pemvidutide, a novel, investigational and peptide-based GLP-1/glucagon dual ...
Sagimet Biosciences, Inc. Class A ( (SGMT) ) has released its Q3 earnings. Here is a breakdown of the information Sagimet Biosciences, Inc.
Viking is also developing VK2809, a novel, orally available ... also referred to as metabolic dysfunction associated steatohepatitis, MASH) and fibrosis. In a Phase 2a trial for the treatment ...
Patients with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis who received a novel ...